AU2017313842A1 - PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS - Google Patents
PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS Download PDFInfo
- Publication number
- AU2017313842A1 AU2017313842A1 AU2017313842A AU2017313842A AU2017313842A1 AU 2017313842 A1 AU2017313842 A1 AU 2017313842A1 AU 2017313842 A AU2017313842 A AU 2017313842A AU 2017313842 A AU2017313842 A AU 2017313842A AU 2017313842 A1 AU2017313842 A1 AU 2017313842A1
- Authority
- AU
- Australia
- Prior art keywords
- subject
- effective amount
- therapeutically effective
- compound
- inti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376732P | 2016-08-18 | 2016-08-18 | |
| US62/376,732 | 2016-08-18 | ||
| PCT/US2017/047584 WO2018035449A1 (en) | 2016-08-18 | 2017-08-18 | Pparϒ agonist for treatment of bone disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017313842A1 true AU2017313842A1 (en) | 2019-03-07 |
Family
ID=61197122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017313842A Abandoned AU2017313842A1 (en) | 2016-08-18 | 2017-08-18 | PPARgamma AGONIST FOR TREATMENT OF BONE DISORDERS |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190167660A1 (https=) |
| EP (1) | EP3500269A4 (https=) |
| JP (2) | JP2019524889A (https=) |
| KR (1) | KR20190065252A (https=) |
| CN (1) | CN109843292A (https=) |
| AU (1) | AU2017313842A1 (https=) |
| BR (1) | BR112019003133A2 (https=) |
| CA (1) | CA3033971A1 (https=) |
| EA (1) | EA201990513A1 (https=) |
| SG (2) | SG10202101500WA (https=) |
| WO (1) | WO2018035449A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| KR102056756B1 (ko) * | 2013-01-30 | 2019-12-17 | 인테크린 테라퓨틱스, 아이엔씨. | 다발성 경화증의 치료를 위한 PPARγ 작용제 |
| ES2785317T3 (es) * | 2014-10-10 | 2020-10-06 | Liminal Biosciences Ltd | Compuestos aromáticos sustituidos y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis |
-
2017
- 2017-08-18 AU AU2017313842A patent/AU2017313842A1/en not_active Abandoned
- 2017-08-18 SG SG10202101500WA patent/SG10202101500WA/en unknown
- 2017-08-18 CA CA3033971A patent/CA3033971A1/en active Pending
- 2017-08-18 BR BR112019003133-2A patent/BR112019003133A2/pt not_active IP Right Cessation
- 2017-08-18 WO PCT/US2017/047584 patent/WO2018035449A1/en not_active Ceased
- 2017-08-18 SG SG11201901328VA patent/SG11201901328VA/en unknown
- 2017-08-18 CN CN201780063392.8A patent/CN109843292A/zh active Pending
- 2017-08-18 EA EA201990513A patent/EA201990513A1/ru unknown
- 2017-08-18 US US16/326,070 patent/US20190167660A1/en not_active Abandoned
- 2017-08-18 KR KR1020197007605A patent/KR20190065252A/ko not_active Ceased
- 2017-08-18 JP JP2019530368A patent/JP2019524889A/ja active Pending
- 2017-08-18 EP EP17842205.1A patent/EP3500269A4/en not_active Withdrawn
-
2022
- 2022-06-03 JP JP2022090843A patent/JP2022116294A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190065252A (ko) | 2019-06-11 |
| EP3500269A4 (en) | 2020-04-15 |
| SG10202101500WA (en) | 2021-03-30 |
| SG11201901328VA (en) | 2019-03-28 |
| EA201990513A1 (ru) | 2019-08-30 |
| US20190167660A1 (en) | 2019-06-06 |
| WO2018035449A1 (en) | 2018-02-22 |
| BR112019003133A2 (pt) | 2019-05-21 |
| JP2022116294A (ja) | 2022-08-09 |
| CA3033971A1 (en) | 2018-02-22 |
| JP2019524889A (ja) | 2019-09-05 |
| CN109843292A (zh) | 2019-06-04 |
| EP3500269A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tabatabaei-Malazy et al. | New horizons in treatment of osteoporosis | |
| Henriksen et al. | Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2 | |
| Girotra et al. | The use of parathyroid hormone in the treatment of osteoporosis | |
| Sato et al. | Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases | |
| Mazziotti et al. | New understanding and treatments for osteoporosis | |
| US7576053B2 (en) | Methods and compositions for treating degenerative bone disorders | |
| John et al. | AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women | |
| Xu et al. | Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis | |
| Kashii et al. | Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report | |
| US20150238478A1 (en) | Ppar gamma agonists for treatment of multiple sclerosis | |
| Zhao et al. | Locally administrated perindopril improves healing in an ovariectomized rat tibial osteotomy model | |
| JP2022116294A (ja) | 骨疾患の治療のためのＰＰＡＲγアゴニスト | |
| Pal et al. | Oral dosing of pentoxifylline, a pan-phosphodiesterase inhibitor restores bone mass and quality in osteopenic rabbits by an osteogenic mechanism: A comparative study with human parathyroid hormone | |
| Idolazzi et al. | Treatment with neridronate in children and adolescents with osteogenesis imperfecta: data from open-label, not controlled, three-year Italian study | |
| JPH069429A (ja) | オステオポローシスの治療方法およびそのための組成物 | |
| RU2693484C1 (ru) | Антагонисты гастрина для лечения и профилактики остеопороза | |
| Ebeling et al. | Teriparatide (rhPTH 1–34) for the treatment of osteoporosis | |
| Appelman-Dijkstra et al. | Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches | |
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| JP6279529B2 (ja) | 虚弱を治療する方法 | |
| Cosman | Parathyroid hormone and abaloparatide treatment for osteoporosis | |
| Cosman | Teriparatide and abaloparatide treatment for osteoporosis | |
| Cosman | Anabolic therapy for osteoporosis: parathyroid hormone | |
| El Miedany | Geroscience and management of osteoporosis in older adults | |
| Inderjeeth et al. | Teriparatide: its use in the treatment of osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PPARGAMMA AGONIST FOR TREATMENT OF BONE DISORDERS |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |